Jeffrey W. Johannes - Concepedia

Concepedia

Author

Jeffrey W. Johannes

AstraZeneca (United States)ORCID

Also Known As

J Johannes, J. Johannes, J.W. Johannes, Jeffrey Johannes, Jeffrey W Johannes, Jeffrey W. Johannes, Jeffrey W. Johannes*, Johannes, J.W.

110

Publications

2.7K

Citations

22

H-Index

36

Concepts

All Affiliations

AstraZeneca (United States)AstraZeneca (United Kingdom)AstraZeneca (Brazil)Université du Québec à Montréal AstraZeneca (Sweden)

JW

About

Jeffrey W. Johannes is an author at AstraZeneca (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	276
2	Engineering	6	6	450
3	Natural Sciences	4	4	154
4	Biochemistry	3	3	125
5	Cell Biology	3	3	115

Jeffrey W. Johannes

×

32

Publications

2.7K

Citations

22

H-Index

	Year	Citations
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia Adriana E. Tron, Matthew A. Belmonte, Ammar Adam, Nature Communications	2018	479
Photoredox Mediated Nickel Catalyzed Cross-Coupling of Thiols With Aryl and Heteroaryl Iodides via Thiyl Radicals Martins S. Oderinde, Mathieu Frenette, Daniel Robbins, Journal of the American Chemical Society	2016	441
Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis Thomas J. Struble, Juan C. Alvarez, Scott P. Brown, Journal of Medicinal Chemistry	2020	236
Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross‐Coupling of Primary Aryl Amines with Aryl Halides Martins S. Oderinde, Natalie H. Jones, Antoine Juneau, Angewandte Chemie International Edition Diverse Aryl IodidesChemical EngineeringCross-coupling ReactionPrimary Aryl AminesEngineering	2016	208
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper Giuditta Illuzzi, Anna D. Staniszewska, Sonja J. Gill, Clinical Cancer Research	2022	157
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs Jeffrey W. Johannes, Amber Balazs, Derek Barratt, Journal of Medicinal Chemistry	2021	129
Effects of Molecular Oxygen, Solvent, and Light on Iridium-Photoredox/Nickel Dual-Catalyzed Cross-Coupling Reactions Martins S. Oderinde, Adrián Varela‐Álvarez, Brian Aquila, The Journal of Organic Chemistry Chemical EngineeringNickel Dual-catalyzed SpEngineeringCross-coupling ReactionPhotochemistry	2015	89
Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross‐Coupling of Primary Aryl Amines with Aryl Halides Martins S. Oderinde, Natalie H. Jones, Antoine Juneau, Angewandte Chemie	2016	76
A Unified and Practical Method for Carbon–Heteroatom Cross‐Coupling using Nickel/Photo Dual Catalysis Randolph Escobar, Jeffrey W. Johannes Chemistry - A European Journal Flow ApparatusEngineeringInorganic PhotochemistryExcited NickelOrganic Chemistry	2020	71
Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology Jeffrey W. Johannes, Lynsie Almeida, Bernard Barlaam, ACS Medicinal Chemistry Letters PharmacotherapyCancer BiologyTumor BiologyVivo PharmacologyCanonical Wnt Pathway	2015	64

Page 1